ReviewInternational journal of methods in psychiatric research2007
Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review.
Review in International journal of methods in psychiatric research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00682591 (Evaluation of Neurocognitive Performance, Quality of Life, and Emotional State in Drug Substituted Patients), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Neurocognitive Performance, Quality of Life, and Emotional State in Drug Substituted Patients (Methadone, Buprenorphine, Suboxone) Under Hepatitis C Therapy (Peginterferon Alfa and Ribavirin)
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Pooled it
- RNA editing blood biomarkers for predicting mood alterations in HCV patients.Journal of neurovirology · 2019Trial
- Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.Journal of gastroenterology and hepatology · 2012Trial
- Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children.Hepatology (Baltimore, Md.) · 2011Trial
- Trial
- Modulation of microglial activation by antidepressants.Journal of psychopharmacology (Oxford, England) · 2022Review
- Feasibility and impact of a guided symptom exposure augmented cognitive behavior therapy protocol to prevent symptoms of pharmacologically induced depression: A pilot study.Cognitive therapy and research · 2019Article
- Recurrence of depressive disorders after interferon-induced depression.Translational psychiatry · 2017Article
- Elevation of Serum Aminotransferase Levels and Future Risk of Death from External Causes: A Prospective Cohort Study in Korea.Yonsei medical journal · 2015Article
- Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.BMC infectious diseases · 2015Observational
- Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C.Pharmacopsychiatry · 2014Article
- Neuropsychiatric side-effects of interferon-alpha treatment: pathophysiology and therapeutic options.Maedica · 2014Article
- Neurological complications of hepatitis C infection.Current neurology and neuroscience reports · 2012Review
- Anemia management in the era of triple combination therapy for chronic HCV.Gastroenterology & hepatology · 2012Article
- A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase.Neuropsychiatric disease and treatment · 2011Article
- Risk factors for the development of depression in patients with hepatitis C taking interferon-α.Neuropsychiatric disease and treatment · 2011Article
- Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.Alimentary pharmacology & therapeutics · 2009Review
- Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, research on interferon (IFN)-induced depressive symptoms in antivirally treated patients suffering from chronic hepatitis C (CHC) has considerably intensified. Profound scientific knowledge of this complication is of great relevance with regard to adherence, compliance, and premature therapy discontinuation. Presently, there is considerable variability of both, the frequency and extent of IFN-induced depression reported in different cohorts of patients. The aim of the presented study was to systematically review recent literature of research within this field; and particularly (1) to identify to what extent methodological bias contributed to inconsistent results in different studies, (2) to critically appraise methods and results of studies published so far, and (3) to suggest directions for future work, especially with respect to alternative and improved methodological approaches. The results of this critical review suggest that the variability of findings seem to be largely due to different study populations, treatment regimens, methodological approaches, and sometimes arbitrary or at least poorly defined choice of screening instruments for depression, particularly criteria for clinically relevant depression (cut-off criteria). Study designs and methodological approaches to investigate IFN-alfa-induced depression in patients with CHC have been incoherent. Future research in this field needs agreement on the use of standardized assessment of IFN-induced depression in CHC. Furthermore, objective criteria and guidelines for the treatment of IFN-induced depression in these patients are needed in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.